MedWatch

CEO counts on sale: “It is about surviving as long as possible”

Danish Methyldetect has developed a technology for early diagnosis of cancer. The plan is to sell it on to a larger player within few years. “We create the startup, we develop the product, and then we leave it. It’s the usual business model for a company like ours,” says the CEO.

Foto: privatfoto

It was a dark and stormy night. This is how Tomasz K. Wojdacz, CEO in Danish company Methyldetect, recalls the day he invented a method to diagnose early stages of cancer. He had come to Denmark from Poland to study biomedicine at Aarhus University, and that dya he was alone in his supervisor’s laboratory.

“It was in the middle of the Danish winter, so it might just have been in the afternoon. In any case, it was pitch-dark,” he tells.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier